POST Online Media Lite Edition


Sygnature Discovery appoints Charles Woler as chairman

Christian Fernsby |
Nottingham, United Kingdom - Sygnature Discovery, an integrated drug discovery solutions provider, has appointed the highly experienced pharmaceutical executive Charles Woler as chairman.

Article continues below

In a broad career, Dr Woler has held multiple key roles in the sector, including CEO at Roche France, Executive Chairman for Europe at SmithKline Beecham PLC, and CEO at Cadus Pharmaceutical in the US

He has also worked in numerous biotech-focused venture capital firms, chairing the advisory committee of the public-private Inserm-Transfert Initiative Investment Committee fund and serving as Vice Chairman of the France Biotech trade association for three years.

In addition, Dr Woler set up French biotech company Neuro3d before selling the business, co-founded Swiss biopharmaceutical firm Inflamalps, and was CEO at Biomnis, one of the largest independent laboratories in Europe.

He gained a PhD in Clinical Pharmacology from the University of Lyon and an MD from Université Paris Diderot (Paris VII), and has since spent more than 35 years in the pharmaceutical, biotech and medical sectors in Europe and North America.

Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021. â– 

 LATEST MOVES FROM United Kingdom 

PA Media Group appoints Emily Shelley to its board
DefiniGEN appoints Chris Kirton as CEO
DAZN Group announces leadership changes
World Mobile announces new CMO
Pepco Group CEO Andy Bond to step down